Syndax Pharmaceuticals SNDX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Syndax Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's return on equity?
- Syndax Pharmaceuticals (SNDX) reported return on equity of -189.5% in Q1 2026.
- How has Syndax Pharmaceuticals's return on equity changed year-over-year?
- Syndax Pharmaceuticals's return on equity decreased by 102.3% year-over-year, from -93.7% to -189.5%.
- What is the long-term trend for Syndax Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's return on equity has grown at a 25.7% compound annual growth rate (CAGR), from -51.6% to -161.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.